Oritavancin, also known as LY333328, is a novel semisynthetic glycopeptide antibiotic. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin was more active than either metronidazole or vancomycin against strains of Clostridium difficile tested. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. The 4'-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria. It also acts by inhibition of transglycosylation and inhibition of transpeptidation.
MedKoo Cat#: 317101
Name: Oritavancin diphosphate
CAS#: 192564-14-0 (diphosphate)
Chemical Formula: C86H103Cl3N10O34P2
Exact Mass: 1790.5641
Molecular Weight: 1989.09
Elemental Analysis: C, 51.93; H, 5.22; Cl, 5.35; N, 7.04; O, 27.35; P, 3.11
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 40.0 | 20.10 |
The following data is based on the product molecular weight 1,989.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
